Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
Five non-ionic surfactants (Surfactants V-IX) were screened for their ability to produce vesicles for the delivery of sodium stibogluconate. Mean vesicle diameter and antimony content were determined prior to in vivo assessment of antiparasitic activity in a mouse model of acute visceral leishmaniasis. V/D suspensions (i.e. stibogluconate loaded vesicles kept in the hydrating drug solution) were more effective against spleen, liver and bone marrow parasites than drug loaded vesicle suspensions that had unentrapped drug removed. A Surfactant IX V/D suspension was the most active antileishmanial preparation causing 74 +/- 10%, 99 +/- 1% and 38 +/- 8% suppression of liver, spleen and bone marrow parasite burdens respectively. Contrary to previous findings, a reduction in splenic and bone marrow parasite burdens was achieved using large vesicles (mean diameter > 800nm). The significance of these results is discussed.
Williams
D M
DM
Department of Immunology, University of Strathclyde, Glasgow.
Carter
K C
KC
Baillie
A J
AJ
D000818:Animals; D000965:Antimony / Q000032:analysis; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use*; D001853:Bone Marrow / Q000469:parasitology; D004337:Drug Carriers; D005260:Female; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008099:Liver / Q000469:parasitology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D010316:Particle Size; D013154:Spleen / Q000469:parasitology; D013501:Surface-Active Agents
D004337:Drug Carriers; D013501:Surface-Active Agents; D000965:Antimony; D000967:Antimony Sodium Gluconate